We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PDUFA NEGOTIATIONS: FDA FOCUSES ON IMPROVED DRUG SAFETY, RISK MANAGEMENT

PDUFA NEGOTIATIONS: FDA FOCUSES ON IMPROVED DRUG SAFETY, RISK MANAGEMENT

June 29, 2006

The FDA is focusing on improved use of epidemiological data and assessment of risk management plans (RMP) as two of the touchstones of its ongoing Prescription Drug User Fee Act (PDUFA) negotiations, a high-ranking agency official said.

The FDA believes that improved drug safety is "front and center" among the agency's priorities over the next year, Scott Gottlieb, the FDA's deputy commissioner for medical and scientific affairs, said at a June 28 conference. In an effort to improve drug safety, the FDA, it its negotiations with Congress on reauthorizing PDUFA, is seeking more user fees to purchase epidemiological databases and to develop a strategy for amending RMPs. PDUFA expires Oct. 1, 2007.

Those initiatives will not come cheap. It can cost the agency $7 million to $10 million to purchase four to five data sets from health insurers, and developing guidance documents is a multimillion dollar undertaking, Gottlieb said.

Having epidemiological data allows the agency to better predict the kinds of problems a drug can cause, Gottlieb told FDAnews. Knowing what the likely adverse events are allows the FDA to better focus its resources on clinical trials necessary to detect problems prior to approval, he said.

The agency also needs industry funds to make a major change in its RMP program. The FDA wants to develop a system to evaluate RMPs one to two years after a drug has been approved to assure that these plans are still effective in protecting patients' safety, Gottlieb said.

The agency does not want to have "a static program" in place. As circumstances change, the FDA wants to be able to adjust the RMPs to ensure safety. This announcement comes weeks after Gottlieb warned that the agency might be overusing RMPs. (http://www.fdanews.com/did/5_127/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing